CHARACTERIZATION OF PAIRED TUMOR AND NONTUMOR CELL-LINES ESTABLISHED FROM PATIENTS WITH BREAST-CANCER

Citation
Af. Gazdar et al., CHARACTERIZATION OF PAIRED TUMOR AND NONTUMOR CELL-LINES ESTABLISHED FROM PATIENTS WITH BREAST-CANCER, International journal of cancer, 78(6), 1998, pp. 766-774
Citations number
30
Categorie Soggetti
Oncology
ISSN journal
00207136
Volume
78
Issue
6
Year of publication
1998
Pages
766 - 774
Database
ISI
SICI code
0020-7136(1998)78:6<766:COPTAN>2.0.ZU;2-V
Abstract
The goal of our study was to develop a panel of tumor cell lines along with paired non-malignant cell lines or strains collected from breast cancers, predominantly primary tumors. From a total of 189 breast tum or samples consisting of 177 primary tumors and 12 metastatic tissues, we established 21 human breast tumor cell lines that included 18 cell lines derived from primary tumors and 3 derived from metastatic lesio ns, Cell lines included those from patients with germline BRCA1 and FH IT gene mutations and others with possible genetic predisposition. For 19 tumor cell lines, we also established one or more corresponding no n-malignant cell strains or B lymphoblastoid (BL) lines, which include d 16 BL lines and 7 breast epithelial (2) or stromal (5) cell strains. The present report describes clinical, pathological and molecular inf ormation regarding the normal and tumor tissue sources along with rele vant personal information and familial medical history. Analysis of th e breast tumor cell lines indicated that most of the cell lines had th e following features: they were derived from large tumors with or with out axillary node metastases; were aneuploid and exhibited a moderate to poorly differentiated phenotype; were estrogen receptor (ER)- and p rogesterone receptor (PR)-negative; and overexpressed p53 and HER2/neu proteins, Of 13 patients with primary breast cancers receiving curati ve intent mastectomies, 7 were dead after a mean period of 10 months. Our panel of paired tumor and non-malignant cell lines should provide important new reagents for breast cancer research. (C) 1998 Wiley-Liss , Inc.